Figure 1.
Time courses of the percentages of phase 2 and phase 3 GCTs sponsored by 20 companies, involving 1) the United States, 2) any of the three European countries having a large number of clinical trials (Germany, France, and the United Kingdom), or 3) any of the East Asian countries/regions.